Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The copper chelate specifically facilitates superoxide dismutase-like activity, quenching reactive oxygen species
253 The first trial enrolled 234 participants (mean age 48 years) who were unwilling or unable to use positive airway pressure (PAP) therapy, and the second group consisted of 235 participants (mean age 52 years) who had been on consistent PAP therapy for at least three months prior to screening and were expected to continue therapy during the trial
FAQ: Q: What is the minimum order quantity
Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study
US$ 22.57
US$ 26.20
US$ 22.42
US$ 20.17
US$ 27.49
